Galapagos News - GXE

Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301

Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301...

Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101

Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101 Additional safety and efficacy...

Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023

Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023 Mechelen, Belgium; 6 December...

Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023

Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023 First nine...

Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma

Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma Transaction would enable...

Galapagos appoints Simon Sturge to its Board of Directors

Galapagos appoints Simon Sturge to its Board of Directors Mechelen, Belgium; 19 September 2023, 22:01 CET; Galapagos NV (Euronext &...

Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023

Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023 Six...

Galapagos announces full year 2022 results and outlook for 2023

Galapagos announces full year 2022 results and outlook for 2023 Key 2022 and post-period events Dr. Paul Stoffelsi appointed as Chief...

Galapagos presented encouraging initial safety and efficacy data at 2023 EBMT-EHA for point-of-care manufactured CAR-T candidate, GLPG5201, in rrCLL

Galapagos presented encouraging initial safety and efficacy data at 2023 EBMT-EHA for point-of-care manufactured CAR-T candidate, GLPG5201, in...

Galapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a CD19 CAR-T candidate manufactured at point-of-care

Galapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a CD19 CAR-T candidate manufactured at point-of-care 6...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Galapagos (GXE)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

GXE News

Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301

Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101

Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023

Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023

Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma

Galapagos appoints Simon Sturge to its Board of Directors

Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023

Galapagos announces full year 2022 results and outlook for 2023

Galapagos presented encouraging initial safety and efficacy data at 2023 EBMT-EHA for point-of-care manufactured CAR-T candidate, GLPG5201, in rrCLL

Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn’s disease

Galapagos receives transparency notification from FMR LLC

Galapagos to present at 41th Annual J.P. Morgan Healthcare Conference

Galapagos receives transparency notification from FMR LLC

Galapagos announces changes to Executive Committee

Galapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a CD19 CAR-T candidate manufactured at point-of-care

GXE Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Galapagos (GXE) News

Galapagos (GXE)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

GXE News

Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301

Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101

Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023

Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023

Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma

Galapagos appoints Simon Sturge to its Board of Directors

Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023

Galapagos announces full year 2022 results and outlook for 2023

Galapagos presented encouraging initial safety and efficacy data at 2023 EBMT-EHA for point-of-care manufactured CAR-T candidate, GLPG5201, in rrCLL

Galapagos announces topline results from Phase 3 DIVERSITY trial of filgotinib in Crohn’s disease

Galapagos receives transparency notification from FMR LLC

Galapagos to present at 41th Annual J.P. Morgan Healthcare Conference

Galapagos receives transparency notification from FMR LLC

Galapagos announces changes to Executive Committee

Galapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a CD19 CAR-T candidate manufactured at point-of-care

GXE Discussion

Your Recent History